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Abstract
The human cytomegalovirus (HCMV) clinical strain Toledo and the attenuated strain AD169 exhibit a striking difference in
pathogenic potential and cell tropism. The virulent Toledo genome contains a 15-kb segment, which is present in all
virulent strains but is absent from the AD169 genome. The pathogenic differences between the 2 strains are thought to be
associated with this additional genome segment. Cytokines induced during viral infection play major roles in the regulation
of the cellular interactions involving cells of the immune and inflammatory systems and consequently determine the
pathogenic outcome of infection. The chemokine RANTES (Regulated on activation, normal T-cell expressed and secreted)
attracts immune cells during inflammation and the immune response, indicating a role for RANTES in viral pathogenesis.
Here, we show that RANTES was downregulated in human foreskin fibroblast (HFF) cells at a later stage after infection with
the Toledo strain but not after infection with the AD169 strain. miR-UL148D, the only miRNA predicted from the UL/b’
sequences of the Toledo genome, targeted the 39-untranslated region of RANTES and induced degradation of RANTES
mRNA during infection. While wild-type Toledo inhibited expression of RANTES in HFF cells, Toledo mutant virus in which
miR-UL148D is specifically abrogated did not repress RANTES expression. Furthermore, miR-UL148D-mediated
downregulation of RANTES was inhibited by treatment with a miR-UL148D-specific inhibitor designed to bind to the
miR-UL148D sequence via an antisense mechanism, supporting the potential value of antisense agents as therapeutic tools
directed against HCMV. Our findings identify a viral microRNA as a novel negative regulator of the chemokine RANTES and
provide clues for understanding the pathogenesis of the clinical strains of HCMV.
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Introduction
Human cytomegalovirus (HCMV) is a member of the b-
herpesvirus family and a ubiquitous human pathogen. After a
primary infection, HCMV establishes lifelong latency, which
seldom causes illness in an immunocompetent host [1,2].
However, HCMV is an infectious pathogen that induces
morbidity and mortality in immunocompromised individuals such
as AIDS patients [3]. HCMV strains display different levels of
virulence, tissue tropism, and pathogenicity depending on their
degree of adaptation in fibroblasts. Injection of the low-passaged
HCMV strain Toledo into healthy adults causes clinically
apparent diseases [4], whereas adults inoculated with the
attenuated HCMV AD169 or Towne strains do not manifest
any clinical symptoms [5,6]. These results indicate that the clinical
Toledo strain is more virulent than the attenuated AD169 strain.
Clinical and attenuated strains of HCMV also differ in their ability
to render infected cells susceptible to the action of natural killer
(NK) cells. Clinical strains confer a strong NK cell resistance,
whereas high-passaged attenuated strains cause only marginal
effects with respect to NK cell recognition [7,8]. This suggests that
the mechanisms employed to evade NK cell lysis may be lost
during in vitro passage of the attenuated viruses. The complete
genome of the laboratory-adapted strain AD169 has been
sequenced [9]. An additional 19 viral genes (UL133 through
UL151), which are absent from AD169, were found in low-
passaged clinical isolates [10]. These genetic differences between
attenuated strains and clinical strains may be implicated in
HCMV-induced immunopathogenesis, as well as in strain-specific
behaviors, such as tissue tropism and the ability to establish
persistent or latent infections [11–13].
When such a virus infects its host, the host immune system is
activated to remove the virus or virus-infected cells. One of the
first lines of effector signals that attract circulating leukocytes to the
site of viral infection is provided by chemokines [14]. Chemokines
are small chemoattractant cytokines that are expressed and
secreted during an inflammatory response. Chemokines attract
specific immune cells during viral infection. In certain inflamma-
tory reactions, proinflammatory cytokines, such as tumor necrosis
factor alpha (TNF-a) and interferon gamma (IFN-c), stimulate the
PLoS Pathogens | www.plospathogens.org 1 March 2012 | Volume 8 | Issue 3 | e1002577expression of RANTES, which is chemotactic for T cells,
eosinophils and basophils [15]. The initiation stage of viral
infection, which includes particle binding and internalization,
activates various responses in the host cells [14].
Viruses can manipulate the cellular interactions involving cells
of the immune systems for their benefit by regulating cellular
chemokines. Regulation of RANTES by HCMV has also been
reported. Billstrom et al. showed that the abortive HCMV added
to endothelial cells was capable of both entering into the host cells
and uncoating. However, the virus was found to be incapable of
repressing the expression of RANTES. The degradation of
RANTES mRNA was also found in endothelial cells infected
with the clinical isolate HCMV 4010 [16]. In contrast, Michelson
et al. showed that the level of extracellular RANTES was reduced
at a later stage after infection of AD169 in fibroblasts without
mRNA degradation. An apparent discrepancy regarding degra-
dation of RANTES mRNA between these two studies might be
due to the genetic polymorphisms among HCMV strains. In
particular, because the predominant function of miRNA is to
induce degradation of target mRNA for reduced protein output
[17], the differential expression of miRNAs among HCMV strains
might account for this discrepancy.
miRNAs are a type of small RNA that regulates a variety of
cellular processes [18,19]. Mature miRNAs are single-stranded
RNAs of 20–24 base pairs that are derived from longer transcripts
processed by the enzymes Drosha and Dicer [20,21]. Mature
miRNA is incorporated into the RNA-induced silencing complex
(RISC) during targeting of transcripts [22]. In the case of complete
homology between miRNA and a target transcript, the target
transcript is cleaved, whereas partial homology can lead to RNA
cleavage or translational inhibition [23]. miRNAs exist in virtually
all organisms including animals, plants and viruses. HCMV
expresses multiple miRNAs during its infectious life cycle. By small
RNA cloning and sequencing technique it was shown that HCMV
expresses 9 miRNA precursors [24]. A bioinformatics analysis
predicted that 2 additional miRNAs are conserved between
HCMV and chimpanzee CMV [25]. Collectively, these 11
miRNA precursors in HCMV lead to 14 mature miRNAs, but
their physiological functions are largely unknown. Interestingly,
miR-UL148D miRNA exists in the 15-kb segment of clinical
strains [24,26] while it is not found in the attenuated AD169
strain. This suggests that miR-UL148D might play a role in the
pathogenicity of the HCMV clinical strains.
In this study, we show that miR-UL148D directly targets
RANTES, thereby inducing degradation of RANTES mRNA.
Accordingly, the level of secreted RANTES was reduced by miR-
UL148D during infection with the Toledo strain. A mutant
Toledo virus with a deleted miR-UL148D gene did not repress
RANTES expression. A PNA-based antisense oligonucleotide
specific to a miR-UL148D reverted miR-UL148D-mediated
downregulation of RANTES during HCMV infection. These
results reveal that the clinical HCMV strain employ an additional
miRNA-based mechanism to modulate the host immune system.
Results
An inverse relationship between RANTES mRNA and
HCMV microRNA miR-UL148D levels
RANTES secretion is reduced by the attenuated HCMV strain
AD169 in HFF cells during the replication phase [27]. Taking
diverse roles of RANTES in immune and inflammatory responses
into consideration and better understanding the virulence and
pathogenicity of the clinical HCMV strain, we tested whether
RANTES expression is also regulated by Toledo, which is the
predominant clinical isolate of HCMV. HFF cells were infected
with wild-type AD169 (WT-AD169) or wild-type Toledo (WT-
Toledo). We employed quantitative RT-PCR to examine the
RANTES mRNA levels. In the WT-AD169-infected cells, the
level of RANTES mRNA increased gradually and peaked at 48 h
post-infection (Figure 1A, triangles). Interestingly, WT-Toledo
infection repressed the expression of RANTES mRNA throughout
the infection with almost nondetectable levels at 48 h post-
infection (Figure 1A, circles). These data suggest that Toledo
might have at least an extra functional gene, which is lacking in
AD169, that inhibits the transcription of RANTES or degrades
RANTES mRNA. The primary function of miRNA is to
destabilize target mRNA for reduced protein output [17]. To
explore whether HCMV miRNAs are related to the regulation of
the expression of RANTES, we performed bioinformatics-based
target site screening. We utilized 2 previously-designed algorithms
for identification of miRNA-mRNA target interaction pairs that
exhibit favorable free energies (DG). The favorable free energies of
the interaction of viral miRNAs with RANTES 39UTR were
estimated using the computational prediction algorithm, RNA22
[28]. Highly favorable free energy is provided by complementary
pairing of miRNA with the 39UTR that further stabilizes target
recognition. Among the 14 miRNAs tested, only miR-UL148D
[24] exhibited highly favorable free energy (DG=235.4 kcal/
mol). As a comparison, this interaction was predicted to be of
higher stability than that observed between a pairing of a well-
known let-7 miRNA with lin-28 mRNA (DG=231.0 kcal/mol)
(data not shown). These results were confirmed by using another
algorithm, RNAhybrid [29]. This RNAhybrid algorithm yields
highly favorable free energies for miR-UL148D (DG=
236.0 kcal/mol). On the basis of computational predictions, we
concluded that miR-UL148D might target the 39UTR of
RANTES.
miR-UL148D expression has been detected by RT-PCR
analysis in other clinical strains [30] and the mature miR-
UL148D sequence is completely conserved among all known
clinical strains (Figure 1C). We determined whether miR-UL148D
is also expressed in Toledo. Total RNA was isolated from Toledo-
infected HFF cells. The mature miR-UL148D was detected by
Author Summary
Unlike the attenuated HCMV strain AD169, the clinical
isolates of HCMV, including the Toledo strain, are virulent
and can cause disease in healthy adults. Toledo differs
from AD169 in that Toledo contains a 15-kb DNA segment,
encoding at least 19 ORFs and a single microRNA known as
miR-UL148D. This 15-kb segment is believed to be a major
determinant of the virulence and pathogenicity of the
Toledo clinical strain. The CC–chemokine RANTES recruits
immune cells during viral infection, suggesting that it may
play a role in virus-related diseases. Here, we show that
RANTES mRNA was degraded in human foreskin fibroblast
cells during infection with Toledo but not during infection
with AD169. The degradation of RANTES mRNA was
mediated by miR-UL148D, the only viral microRNA
predicted from the 15–kb segment of the Toledo genome.
Accordingly, the levels of secreted RANTES in infected cells
with ToledoDmiR-UL148D in which miR-UL148D was
deleted were higher than those in infected cells with
Toledo. Our results reveal that a viral microRNA could be a
novel potential therapeutic target and provide important
insights into understanding the differences in pathogenic
potential between clinical and attenuated strains.
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PLoS Pathogens | www.plospathogens.org 2 March 2012 | Volume 8 | Issue 3 | e1002577Figure 1. Inverse correlation between RANTES mRNA and miR-UL148D expression at a later stage during Toledo infection. (A) HFF
cells were infected with WT-AD169 (triangles) or WT-Toledo (circles). RANTES mRNA at indicated time of post-infection (hpi) was quantified by
quantitative RT-PCR and data were normalized to GAPDH mRNA (RANTES/GAPDH). Values represent the average 6 S.D. of triplicate experiments. (B)
The predicted duplex of the 39UTR of RANTES and miR-UL148D-WT. The indicated free energy value was calculated using RNA22 (http://cbcsrv.
watson.ibm.com/rna22.html). (C) Alignment of miR-UL148D stem-loop sequence of various HCMV clinical strains. We analyzed the genomic
sequences of several HCMV clinical strains from GenBank (Toledo GU937742.1, TB40/E AY446866.1, Merlin AY446894.2, JHC HQ380895.1, VR1814
GU179289.1). The conserved sequence (gray) and non-conserved sequence (blue) is shown. Mature miR-UL148D sequence is highlighted in red. (D)
The detection of miR-UL148D in Toledo-infected HFF cells was assessed using the RNase protection assay as described under ‘‘Materials and
Methods.’’ 5S rRNA bands stained with ethidium bromide are presented as a loading control. Using the same RNA samples, the RANTES mRNA and
GAPDH mRNA were measured by RT-PCR (lower panel). NI indicates non-infected control.
doi:10.1371/journal.ppat.1002577.g001
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UL148D of ,22 bp size that is shorter than the original miR-
UL148D probe of 27-bp (Figure 1D, first panel). The expression of
miR-UL148D increased throughout the infection and peaked at
72 h post-infection (Figure 1D, first panel, lanes 2–4). RT-PCR
analysis of the same samples revealed that the expression level of
RANTES mRNA is inversely correlated with the expression level
of miR-UL148D (Figure 1D, third panel). These data suggest that
Toledo-induced downregulation of RANTES may be a conse-
quence of miR-UL148D expression.
miR-UL148D targets the 39UTR of RANTES
To test whether the 39UTR of RANTES is a target of miR-
UL148D, the entire RANTES 39UTR was subcloned immediately
downstream of the firefly luciferase open reading frame (ORF),
and miR-UL148D was cloned into the pSuper-retro vector as a
22-nucleotide mature form. A luciferase reporter vector containing
the 39UTR of RANTES was transfected into 293T cells with
varying quantities of wild-type miR-UL148D (miR-UL148D-WT)
or control seed binding mutant miRNA (miR-UL148D-mut).
The transfected cells were lysed and appropriate substrates were
added into the lysates in order to measure luciferase activity. Dose-
dependent experiments demonstrated that the relative luciferase
activity was significantly decreased in the presence of miR-
UL148D (Figure 2A, black bars). In contrast, no reduction was
observed in miR-UL148D-mut-transfected cells (Figure 2A, gray
bars). Thus, the 39UTR of RANTES has a specific binding site for
miR-UL148D, indicating that it may be a target of miR-UL148D.
To confirm that the 39UTR of RANTES contains a functional
target site for miR-UL148D, we generated a seed-binding mutant
of the 39UTR of RANTES (RANTES-39UTR-mut) (Figure 2B).
After co-transfection of both the RANTES 39UTR-mut and miR-
UL148D, the luciferase activity was measured. As expected, miR-
UL148D-WT did not repress the luciferase activity of RANTES-
39UTR-mut-expressing cells (Figure 2C, lane 5), whereas the
luciferase activity of wild type RANTES 39UTR (RANTES-
39UTR-WT)-expressing cells was downregulated in the presence
of miR-UL148D-WT (Figure 2C, lane 2). These data demonstrate
that miR-UL148D targets RANTES specifically at the predicted
target sequence identified in the 39UTR.
miR-UL148D inhibits RANTES secretion
As demonstrated above, miR-UL148D represses luciferase
activity in cells expressing the 39UTR of RANTES downstream
of a luciferase reporter gene (Figure 2, A and C). To ascertain
whether miR-UL148D is sufficient to downregulate the level of
RANTES protein, we examined the level of RANTES secreted
into culture supernatants in the presence of miR-UL148D. We
generated a RANTES-expressing vector which includes the
39UTR region and tested whether the ectopic expression of
miR-UL148D in 293T cells reduces the ectopic expression of
RANTES. After transfection of miR-UL148D into 293T cells with
the S
35-radioisotope, secreted RANTES was immunoprecipitated
with anti-RANTES antibody. Northern blot analysis validated the
expression of miR-UL148D-WT and miR-UL148D-mut in
transfected cells (Figure 3A, bottom panels). The amount of
precipitated RANTES decreased in the presence of miR-UL148D
(Figure 3A, compare lane 3 and lane 4). In contrast, miR-
UL148D-mut did not affect the secretion of RANTES (Figure 3A,
lane 5). These results indicate that miR-UL148D downregulates
the expression of RANTES protein through its miRNA function.
Next, we determined whether the reduction of RANTES by
miR-UL148D is caused by specific binding of miR-UL148D to the
seed region of RANTES 39UTR. After co-transfection of
RANTES-39UTR-WT or RANTES-39UTR-mut with miR-
UL148D-WT or miR-UL148D-mut, the labeled media of the
transfected cells were immunoprecipitated with the anti-RANTES
antibody. Co-transfection of both RANTES-39UTR-WT and
miR-UL148D-WT resulted in reduced levels of secreted
RANTES. miR-UL148D-mut did not affect the expression of
RANTES-39UTR-WT (Figure 3B, compare lane 1 and 2). As
designed, miR-UL148D-mut was able to prevent the expression of
RANTES-39UTR-mut (Figure 3B, compare lane 3 and lane 4).
These results show that the 39UTR of RANTES contains a
specific target site for miR-UL148D.
To elucidate whether miR-UL148D reduces RANTES expres-
sion by translation inhibition or mRNA degradation, we
determined RANTES mRNA levels in 293T cells expressing
either miR-UL148D-WT or miR-UL148D-mut. RANTES-
39UTR-WT and RANTES-39UTR-mut were transfected into
293T cells along with either miR-UL148D-WT or miR-UL148D-
mut. After RNA extraction from transfected cells, RANTES
mRNA levels were measured by RT-PCR. The level of RANTES-
39UTR-WT transcripts was decreased in the presence of miR-
UL148D-WT but not in the presence of miR-UL148D-mut
(Figure 3C, compare lane 3 and lane 4). As expected, miR-
UL148D-mut targeted only RANTES-39UTR-mut mRNA but
not RANTES-39UTR-WT for degradation (Figure 3C, compare
lane 4 and lane 7). These results indicate that miR-UL148D
mediates RANTES mRNA degradation but not translational
repression.
RANTES expression is repressed by miR-UL148D during
authentic viral infection
We have shown that miR-UL148D encoded by an expression
vector inhibits the secretion of RANTES. We determined whether
the expression of RANTES is affected by miR-UL148D during
viral infection. We initially utilized a mutant virus (Toledo-
DUL150) in which the UL150 ORF region containing miR-
UL148D was deleted. The infected cells with ToledoDUL150
showed an increased capacity to accumulate RANTES in culture
media compared with the cells infected with Toledo-WT or a
revertant of ToledoDUL150 (Figure S1).
To exclude the possibility that the deletion of the UL150 ORF
affected RANTES level, we generated a mutant virus (Toledo
DmiR-UL148D) in which miR-UL148D was specifically abrogat-
ed but UL150 ORF was intact and its revertant virus (Toledo-
Revertant). To this aim two point mutations were engineered at
the wobble positions of UL150 ORF that comprise the mature
sequence of miR-UL148D (Figure 4A). RNA protection analysis
confirmed that miR-UL148D was expressed in HFF cells infected
with Toledo-WT or Toledo-Revertant but not with ToledoDmiR-
UL148D (Figure 4B, top panel). ToledoDmiR-UL148D and
Toledo-Revertant virus displayed phenotypes similar to the
parental Toledo-WT in viral immediate-early (IE) and late (gB)
gene expression and viral replication capacity (Figure 4B, bottom
panels and Figure 4C). The amount of RANTES protein secreted
into culture supernatants of infected HFF cells was assessed by
ELISA. We found that in ToledoDmiR-UL148D–infected cells,
the amount of accumulated RANTES was significantly higher at
24–72 h post-infection than that in the Toledo-WT–infected cells
(Figure 4D). qRT-PCR analysis revealed that RANTES mRNA
level was also significantly higher in ToledoDmiR-UL148D–
infected cells than in Toledo-WT or Toledo-Revertant-infected
cells (Figure 4E). These data demonstrate that Toledo microRNA
miR-UL148D inhibits RANTES secretion by mediating degrada-
tion of RANTES mRNA during infection.
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PLoS Pathogens | www.plospathogens.org 4 March 2012 | Volume 8 | Issue 3 | e1002577Figure 2. RANTES-39UTR is a target of miR-UL148D. (A) 293T cells were co-transfected with the Renilla luciferase expression vector and firefly
luciferase vector expressing normal RANTES-39UTR (RANTES-39UTR-WT) and either miR-UL148D, miR-UL148D-mut, or siGFP as a negative control
(mock, white bar). The relative luciferase activity was calculated as a ratio of firefly to Renilla luciferase activity. (B) Mutations in the 39-UTR of RANTES
and miR-UL148D. (C) After transfection with RANTES-39UTR-WT (white bars) or RANTES-39UTR-mut (gray bars), cells were re-transfected with miR-
UL148D-WT or miR-UL148D-mut. The cells were lysed, and firefly luciferase activity was measured and normalized to Renilla luciferase. Data represent
the mean 6 S.E. of four independent experiments (*statistically significant difference between cells expressing miR-control and those expressing miR-
UL148D (P,0.05 by Student’s t-test, NS; non-specific).
doi:10.1371/journal.ppat.1002577.g002
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PLoS Pathogens | www.plospathogens.org 5 March 2012 | Volume 8 | Issue 3 | e1002577Figure 3. The secretion of RANTES is inhibited by miR-UL148D. (A) 293T cells were co-transfected with RANTES expressing vector including the
39UTR and either miR-UL148D-WT or miR-UL148D-mut. The culture supernatant of the radioisotope-labeled cells was immunoprecipitated for RANTES
using anti-RANTES or IgG (as an isotype control). GAPDH was immunoprecipitated by anti-GAPDH for a loading control. Northern blots were performed
toconfirmtheexpressionofmiRNAs.(B)293Tcellswereco-transfectedwithbothRANTES-39UTR-WTorRANTES-39UTR-mutandmiR-UL148D-WTormiR-
UL148D-mut. The culture supernatant of the isotope-labeled cells was immunoprecipitated for RANTES. GAPDH was immunoprecipitated by anti-
GAPDH for a loading control. Similar results were obtained in two independent experiments. (C) mRNAs were extracted from the same samples used in
Figure 3B. RANTES mRNA was measured by RT-PCR. To normalize the quantity, GAPDH mRNA was used as a loading control.
doi:10.1371/journal.ppat.1002577.g003
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PLoS Pathogens | www.plospathogens.org 7 March 2012 | Volume 8 | Issue 3 | e1002577miR-UL148D–mediated downregulation of RANTES is
reversed by PNA-based antisense inhibitor during HCMV
infection
Peptide nucleic acid (PNA), which is soluble, stable, specific to
DNA or RNA and probably non-immunogenic, is known to
inhibit miRNA function by an antisense mechanism through
complementary binding of the PNA to the miRNA sequence [31].
To evaluate the therapeutic potential of PNA-based antisense
oligonucleotides, we tested whether a miR-UL148D-specific PNA
could restore RANTES expression during HCMV infection. We
designed a PNA specific to miR-UL148D (PNA-anti-miR-
UL148D) and a scrambled PNA (PNA-control) as a negative
control. PNA-control or PNA-anti-miR-UL148D was transfected
to HFF cells for 2 days before HCMV infection. At 48 h post-
infection, total RNA and culture media were harvested for analysis
by qRT-PCR and ELISA. In the presence of PNA-anti-miR-
UL148D, secreted RANTES protein and RANTES mRNA were
significantly increased (Figure 5A and B). The reduction of miR-
UL148D level in HFF transfected with PNA-anti-miR-UL148D
was confirmed by an RNase protection assay (Figure 5C). These
results suggest that PNA-based antagonist to viral miRNA could
be developed as a useful tool to counteract miRNA-based immune
evasion strategies by viruses.
Discussion
In this study, we report that infection with Toledo, a virulent
clinical HCMV strain, induces degradation of RANTES mRNA
in HFF cells, thereby downregulating the level of the secreted
RANTES. Moreover, we show that the degradation of RANTES
mRNA is mediated by HCMV-miR-UL148D, which resides in
the additional DNA segment of ,15 kb that is missing in the
attenuated HCMV strains such as AD169.
Abortive HCMV added to endothelial cells is capable of both
entering into the host cells and uncoating, but cannot repress the
expression of RANTES [16]. In contrast, replicative HCMV
infection induces cells to express significantly lower levels of
RANTES [16]. These observations have led to the suggestion that
HCMV encodes functional genes that can downregulate
RANTES expression. In fact, HCMV appears to have developed
several mechanisms for modulating RANTES at different stages of
infection. The HCMV immediate-early 2 protein IE86 suppresses
virus-induced RANTES expression [32]. HCMV also encodes
US28 that is a receptor for RANTES. US28 binds and internalizes
secreted RANTES, resulting in depletion of RANTES from the
environment of HCMV-infected cells [33,34]. In addition,
HCMV encodes pUL21.5 protein that functions as a decoy
receptor for RANTES. By binding to the RANTES receptor,
pUL21.5 blocks the interaction of RANTES with the RANTES
receptor [35]. Moreover, HCMV significantly reduces the cell-
surface expression of CC chemokine receptor 1 and RANTES
receptor through the internalization of receptors [36]. The
multiple strategies employed by HCMV ORF gene products for
RANTES regulation paradoxically underscore a critical role for
RANTES in host defense against HCMV infection.
Our work identifies a viral miRNA, miR-UL148D, as a novel
negative regulator for RANTES expression. To date, 14 miRNAs
have been found in HCMV [24,25], but their functions remain
poorly understood. It is noteworthy that, among the 14 miRNAs,
miR-UL148D is found only in clinical HCMV strains. Compar-
isons of nucleotide sequences revealed that the clinical Toledo
genome contains a 15-kb DNA segment that is absent from the
attenuated strain AD169 genome. This additional Toledo
sequence encodes at least 19 ORFs and is found in all clinical
strains [10]. This region is associated with strain-specific tissue
tropism and immunopathogenesis [37,38]. Interestingly, miR-
UL148D exists in this genomic region of clinical strains [26].
Our findings may provide an explanation for the previous
seemingly contradictory observations made by others. Michelson
et al. [27] showed that the levels of both RANTES mRNA and
RANTES protein are increased immediately after infection of
AD169 in fibroblasts. In addition, they observed that extracellular
accumulation of RANTES protein is downregulated late during
HCMV infection, whereas synthesis of RANTES mRNA remains
unchanged. In contrast, Billstrom and Worthen [16] found that
RANTES mRNA is degraded in endothelial cells infected with the
clinical isolate HCMV 4010. This result is consistent with our
observations of the clinical Toledo strain (Figure 1). Our data
demonstrate that the level of RANTES mRNA is downregulated
in cells infected with Toledo but not with the AD169 in which an
additional ,15 kb sequence is absent. Unlike wild-type Toledo,
ToledoDmiR-UL148D virus did not cause a decrease in relative
mRNA and secreted protein levels (Figure 4). Thus, our work
shows that the apparent discrepancy in those studies is attributable
to the genomic differences between the clinical strain and the
attenuated strain, and more specifically, the presence of clinical
strain-specific miR-UL148D.
High-passaged laboratory strains (AD169 and Towne) and low-
passaged clinical strains (Toledo) exhibit a significant difference in
their pathogenicity. For instance, Toledo grows to high titers in
implanted human thymus and liver tissues in SCID-hu mice,
whereas AD169 failed to replicate in human thymus and liver
implants [26]. The pathogenic differences between the 2 strains
are believed to be due to the existence of this additional 15-kb
DNA segment. Consistent with this notion, this 15-kb genomic
region encodes three envelope proteins UL128, UL130 and
UL131. They form gH/gL/UL128/UL130/UL131 protein
complex and the complex is required for entry in epithelial and
endothelial cells [39]. Stanton et al. reported that HCMV clinical
strain Merlin acquired mutations in UL128, UL130 or UL131,
which inhibited virus growth specifically in fibroblast cells [40].
It is noteworthy that a few genes whose functions were described
among 19 ORFs to date are related to cytokines or chemokines.
The UL146 and UL147 genes encoded in this region are a-
(CXC)-chemokine viral homologues, which can influence host
immune responses by impairing the trafficking of peripheral blood
Figure 4. miR-UL148D inhibits RANTES expression during viral infection. (A) Genomic location of UL150 and miR-UL148D (upper panel).
The predicted mature sequence of miR-UL148D (blue) and its mutated residues at wobble position are shown (red) (bottom panel). (B) HFF cells were
infected with Toledo-WT, ToledoDmiR-UL148D or Toledo-Revertant. After extracting miRNAs from the infected cells, the detection of miR-UL148D
was assessed using the RNase protection assay as described under ‘‘Materials and Methods.’’ 5S rRNA was presented as a loading control stained by
ethidium bromide. IE1 and gB gene expression was analyzed by RT-PCR. (C) Growth curves of Toledo-WT, Toledo-DmiR-UL148D and Toledo-
Revertant. HFF cells were infected with wild-type, mutant and revertant viruses at an MOI of 2. The total number of cell-free viruses in the
supernatants of infected cultures was determined by limiting dilution analyses. (D, E) After HFF cells were infected with Toledo-WT (white bars),
ToledoDmiR-UL148D (light gray bars) and Toledo-Revertant (dark gray bars), culture supernatants were harvested at the indicated post-infection
time. The accumulated RANTES in supernatants was quantified by ELISA (D). RANTES mRNA level was detected by qRT-PCR (E). NI indicates non-
infected control. Similar data were obtained in three independent experiments and the bars indicate mean 6S.D.
doi:10.1371/journal.ppat.1002577.g004
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homologue of the herpes simplex virus entry mediator, a member
of the tumor necrosis factor (TNF)-a-like receptor superfamily
[42]. However, a ligand for UL144 has not yet been identified,
and the function of UL144 is still unknown [43]. Given that
cytokines and chemokines are the first line of host defense and
subsequently govern the downstream events of immune responses,
we propose that some of the additional ORFs in the 15-kb segment
could possess cytokine-related functions. Although the physiolog-
ical function of UL150 is unknown, it seems that at least UL150 is
not directly involved in the RANTES regulation because
RANTES was detected at comparable levels in both Toledo
DmiR-UL148D and ToledoDUL150-infected cells (Figure 4 and
Figure S1). Our results demonstrate that HCMV clinical strains
encode a RANTES-targeting viral miRNA. This finding adds
another dimension to the reported viral immunoevasive strategies
Figure 5. PNA-based antisense oligonucleotides specific to miR-UL148D revert Toledo-induced inhibition of RANTES production. 2
days before HCMV infection, PNA-control or PNA-anti-miR-UL148D was transfected to HFF. After 48 h of infection, culture media and total RNA were
analyzed by ELISA (A) and qRT-PCR (B). Down-regulation of miR-UL148D in the presence of PNA was detected by RNase protection assay (C). NI
indicates non-infected control. Similar data were obtained in three independent experiments and the bars indicate mean 6S.D.
doi:10.1371/journal.ppat.1002577.g005
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immune responses. Considering the specificity, non-immunoge-
nicity and relative ease of manipulation of miRNA, a better
understanding of the RANTES regulation by miR-UL148D could
provide the means for immunosuppressive therapy.
Materials and Methods
Cells and antibodies
The human embryonic kidney fibroblast cell line 293T (293T)
was maintained in DMEM medium (Hyclone) containing 7.5%
fetal bovine serum (HyClone Laboratories, Logan, UT), 2 mM L-
glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin.
Human foreskin fibroblast (HFF) cells (passage 8–10) were grown
in DMEM supplemented with 10% FBS under 5% CO2 at 37uC.
Transient transfection was performed using Lipofectamine
(Invitrogen) according to the manufacturer’s instructions. HEK
293T cells seeded on 60-mm culture dishes were grown to 80%
confluence and transfected with proper vector using Lipofecta-
mine 2000 (Invitrogen). After 24 h, the cells were harvested for the
luciferase assay. Anti-RANTES monoclonal antibody (sc-32246)
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-IE1 antibody (MAB810R) was purchased from Chemicon.
Normal mouse IgG was purchased from Sigma-Aldrich.
Virus amplification and infection
A BAC vector including the Toledo strain genome was
introduced into human foreskin fibroblast cells (HFF cells) by
electroporation (Bio-Rad). After 3 weeks, culture supernatants
were collected and used for re-infection of fresh HFF cells. After 3
weeks, culture supernatants were collected and virus titers were
measured. The virus titers were determined as infectious units
after the measurement of the IE1-positive cells in the infectious
center assays using HFF cells. To detect the expression of
RANTES, HFF cells were infected with the Toledo strain as 2
MOI (multiple of infection).
Dual luciferase assay
The full-length 39-untranslated region (39UTR) of the RANTES
gene was amplified by PCR from HFF cDNA using a pair of
primers (forward: GATGGAGAGTCCTTGAACCTGAAC;
and reverse: TTTTTTTTTTATGGTTGCATTGAGAACTTT).
Cells were co-transfected with 2.5 ng of the vector pGL3-Basic
fused RANTES 39UTR, 0.5 ng of Renilla luciferase vector, pRL-
CMV (Promega) and a vector expressing miR-UL148D. Firefly
activities were normalized for transfection efficiency using Renilla
activity. After 16 h post-transfection, the cells were pelleted, washed
in Dulbecco’s phosphate-buffered saline and lysed in 16 passive
lysis buffer (Promega). The firefly and Renilla luciferase activities
were determined according to manufacturer’s instructions (Dual-
Luciferase Reporter Assay System, Promega) using a luminometer
(Berthold Technologies). The relative luciferase activity was
calculated from the firefly luciferase activity of RANTES 39UTR/
construct Renilla luciferase activity of co-transfected pRL-CMV)/
(firefly luciferase of mock vector pGL3-Basic/Renilla luciferase
activity of co-transfected pRL-CMV).
Retrovirus production
Retroviruses encoding hairpin miRNA were constructed using
the pSUPER.retro.puro vector system (OligoEngine, Seattle, WA).
A double-stranded hairpin oligonucleotide designed to express the
miR-UL148D (TCGTCCTCCCCTTCTTCACCG) or miR-
UL148D-mut (TCGTGGACCCCTTCTTCACCG) was cloned
into the BglII/HindIII sites of pSUPER.retro.puro. A control
miRNA was constructed, which contains a 19-bp target sequence
to target the GFP molecule. Correct insertion of the oligonucleo-
tides was confirmed by DNA sequencing. pSuper-retro viruses
were produced in Phoenix-Ampho packaging cells.
Northern blot and RT-PCR
Extracted total RNA from HFF or 293T was resolved on 15%
acrylamide, 8 M urea gel, transferred onto nylon membranes, and
UV cross-linked. [c-
32P]ATP labeled antisense RNA as a probe
for each miRNA was purchased from Cosmo Genetech (Seoul,
Korea). Hybridization was performed in the hybridization solution
overnight at room temperature and the FUJI BAS film was
exposed for 1 day. 5S rRNA bands stained with ethidium bromide
are presented as a loading control for normalization.
DNase-treated total RNA was reverse-transcribed with oligo
dTs. The RT reaction was carried out at room temperature for
10 min. The reaction mixtures were then heated in a thermal
cycler at 42uC for 15 min and 99uC for 5 min and then cooled at
5uC for 5 min. After adding specific primers and PCR reagents,
the mixture was denatured at 95uC for 4 min. The mixture was
then denatured at 95uC for 1 min, annealed at 55uC for 1 min,
and extended at 72uC for 1 min. After 25 cycles, the PCR mixture
was incubated at 72uC for 7 min. To confirm the identity of the
amplified cDNAs, each insert product was directly sequenced
using a specific primer sequence or asymmetrically cut with
restriction enzymes.
The primers for RT-PCR were as follows: HCMV IE1
(forward, GTCAGGTCCACCACTGACAC; reverse, TCATAT-
TAAAGGCGCCAGTG), HCMV gB (forward, AACGCGGC-
TGTAAGAACTGT; reverse, ACGAGGGCATCATGGTAG-
TC), GAPDH (forward, ATCATC CCTGCCTCTACTGG;
reverse, GTCAGGTCCACCACTGACAC).
RNase protection assay
Total RNA was isolated from Toledo-infected HFF cells at
various post-infection times. The mirVana miRNA probe
construction kit (Ambion) was used to synthesize the
32P-labeled
miR-UL148D antisense probe (CGGUGAAGAAGGGGAG-
GACGACCAGAG). This probe was designed so that an obvious
size difference is detectable between the full-length undigested
probe and the protected fragment after RNase digestion. Probe
hybridization and RNase protection was then carried out using the
mirVana miRNA detection kit (Ambion) according to the
manufacturer’s instructions. Briefly, the total RNA was incubated
at 42uC for hybridization to the miR-UL148D-specific probe.
After hybridization, unhybridized RNA and excess RNA probe
were removed by RNase digestion. The double-stranded product
was resolved in a 12% polyacrylamide, 8 M urea denaturing gel
and visualized using autoradiography.
Quantitative real-time PCR
RNA isolation from HCMV-infected cells was performed
according to the manufacturer’s instructions (Invitrogen). Viral
RNA was quantified by qRT-PCR using the iScript cDNA
synthesis kit (Bio-Rad) for 2 h at 42uC. cDNA was amplified with
human RANTES-specific primers (forward, CTCATTTGC-
TACTGC CCTCTGCGCTCCTGC; reverse, GCTCATCTC-
CAAAGAGTTGATGTACTC), HCMV IE1-specific primers
(forward, GTCAGGTCCACCACTGACAC; reverse, TCATAT-
TAAAGGCGCCAGTG), and GAPDH-specific primers (forward,
ATCATC CCTGCCTCTACTGG; reverse, GTCAGGTCCAC-
CACTGACAC). Quantification of HCMV RNA was normalized
with GAPDH RNA as an internal control. Reactions were
performed by the Lightcycler PCR (Roche) using the following
Modulation of RANTES by HCMV miR-UL148D
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follows: 95uC for 10 s, 53uC for 10 s, and 72uC for 25 s.
Computational prediction
The online target prediction algorithm RNA22 (http://cbcsrv.
watson.ibm.com/rna22.html) and RNAhybrid (http://bibiserv.
techfak.uni-bielefeld.de/rnahybrid/submission.html) were used to
predict potential target sites. HCMV 14 miRNAs were used as
target miRNAs [24,44].
Viral mutagenesis
To generate the deletion mutant virus of the miR-UL148D
(ToledoDmiR-UL148D), UL150 region encoding miR-UL148D
was deleted in the Toledo bacterial artificial chromosome (BAC)
using rpsL-neo cassettes. Briefly, rpsL-neo cassettes were PCR
amplified by using primers containing homology arms consisting
of 50 nucleotides upstream and downstream of the target gene plus
24 nucleotides homologous to the rpsL-neo cassette. The amplified
DNA fragments were introduced into E. coli DH10b cells
containing wild-type Toledo-BAC for recombination by electro-
poration using Gene Pulser II (Bio-Rad). The intermediate
Toledo-BAC construct containing the rpsL-neo cassette was
selected on Luria broth (LB) plates containing kanamycin.
UL150 region in Toledo-BAC was destroyed by insertion of
rpsL-neo cassette. We also generated Toledo-Revertant BAC by
the same method. Deletion of miR-UL148D was confirmed by
RNase protection assay using specific probe.
Transfection of miRNA inhibitor PNA
PNA miRNA inhibitors were purchased from Panagene Inc.
The miR-UL148D-specific inhibitor sequence is 59-RRRQR-
RKKR-OO-GTGAAGAAGGGGAGGACG-39 and the scram-
bled control PNA sequence is 59-RRRQRRKKR-OO-TA-
GAGCTCCCTTCAATCCAAA-39. One day before transfection,
HFF cells were seeded onto a 24-well plate in appropriate
complete growth medium without antibiotics. PNAs transfection
was performed using Dharmafect 1 reagent (Dharmacon). PNA
miRNA inhibitor was added into the culture medium at a final
concentration of 500,2000 nM. Cells were incubated at 37uC for
48 h prior to viral infection. A miRNA isolation kit (Invitrogen)
was used to isolate miRNA from total RNA.
Enzyme-linked immunosorbent assays (ELISA)
ELISA was used to measure the expression level of secreted
RANTES. A RANTES ELISA kit was purchased from Thermo
Fisher Scientific Inc. (Rockford, IL). Culture media of transfected
or infected cells were collected and incubated with RANTES
antibody on the plate. Each well was washed with the washing
buffer provided in the ELISA kit. After incubation of HRP-
conjugated antibody, TMB substrate was added into each well.
Absorbance was measured using a microplate reader, iMARK
(Bio-Rad) at a wavelength of 450 nm.
Immunoprecipitation
Cells were labeled with [
35S]methionine and [
35S]cysteine and
lysed in 1% NP-40 in PBS supplemented with protease inhibitors.
After preclearing, samples were incubated with the appropriate
antibodies for 2 h at 4uC before Protein G-Sepharose beads were
added. Beads were washed four times with 0.1% NP-40 in PBS
and bound proteins were eluted by boiling in SDS sample buffer.
Proteins were separated by SDS-PAGE.
Supporting Information
Figure S1 Generation of mutant virus lacking the UL150
ORF region that contains miR-UL148D. (A) A schematic
diagram of the ToledoDUL150 and its revertant BAC construct.
(B) Deletion of miR-UL148D was confirmed by RNase protection
assay using specific probe (upper panel). IE gene expression was
analyzed by immunobloting (bottom panel). (C) The amount of
secreted RANTES in culture media was determined by ELISA.
(TIF)
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